Liquid pharmaceutical compounds, including at least one sglt-2 inhibitor and one or more bipolar organic solvents, wherein at least one sglt-2 inhibitor contains 1-cyano-2 - (4-cyclopropane-benzene) - 4 - (b-d-glucose-1-il) - benzene (1) in the formula,And the related manufacturing process of liquid drug synthesis and its medical use. 13. Claim 13: according to any one of claims 1 to 12, the composition of liquid medicine is characterized by (I) 0.5-5.0 g / 100 ml (% P / P),Preferably 1-cyano-2 - (4-cyclopropyl-benzene) - 4 - (b-d-glucose-1-il) - benzene； (II) 10-60g / 100ml (% P / P),Preferably 35-60g / 100ml (% P / P),Preferably, propylene glycol 50-60g / 100ml (% P / P)； (III) 0-60g / 100ml (% P / P),Preferably 0-52g / 100ml (% P / P) glycerin； (IV) 0-20g / 100ml (% P / P),Preferably 0-15g / 100ml (% P / P),Preferably, 0-10g / 100ml (% P / P),Preferably 0-8g / 100ml (% P / P) ethanol； (V) 0-1g / 100ml (% P / P),Preferably 0-0.15g/100ml (% P / P) seasoning and / or sweetener, preferably a combination of "honey taste, lemon / Savoy taste, jasmine taste, lavender taste, mint taste, raspberry taste, lemon taste, herbal taste". 2. Sucrose and / or aspartame；(VI) 0-52 g / 100 ml (% P / P),Preferably water shock absorber 0-40g / 100ml (% P / P), preferably acid citric acid shock absorber 6.0 or phosphoric acid shock absorber 6.8； (VII) 0-10g / 100ml (% P / P),Preferably 0-8g / 100ml of dissolver (% P / P), preferably selected from this group, which includes: "surface activity, cationic surface activity, non-ionic surface activity, hydrogenated castor oil, polyoxy polyoxypropylene copolymer, polyethylene and / or propylene glycol derivatives",The best choice is from the "SDS" group.Cremophor RH 40,polysorbate 20, Lutrol F 68 (poloxamer 188),Peg 300 and / or propylene glycol monolaurate"；(VIII) 0-5 g / 100 ml (% P / P),Preferably 0-0.5g/100ml viscosity enhancer (% P / P), preferably selected from the group "inorganic gel maker, organic gel maker and / or cellulose derivat
